創傷護理生物製劑市場機會、成長要素、產業趨勢分析及2026-2035年預測

全球創傷護理生物製劑市場預計到 2025 年將達到 20 億美元，並有望以 5.9% 的複合年成長率成長，到 2035 年將達到 35 億美元。

隨著複雜和慢性傷口的先進治療方法在醫療保健系統中日益重要，醫療保健產業正經歷成長。燒傷發生率的上升，尤其是在醫療資源匱乏的地區，推動了對傷口生物製劑的需求成長。治療延誤、基礎設施不足和高感染風險常常使癒合過程複雜化，增加了對創新生物干預措施的需求。這些解決方案因其能夠促進組織修復和改善復原效果而備受關注。此外，人口老化也對市場動態產生了顯著影響，因為老年人更容易患上慢性傷口，例如壓瘡和糖尿病併發症。再生醫學日益受到臨床關注，加上生物工程產品的進步，進一步促進了這些產品的應用。隨著醫療專業人員將快速癒合和減少併發症放在首位，生物創傷護理產品正成為現代治療方案中不可或缺的一部分，從而推動了市場的長期成長。

創傷護理生物製劑是一種先進的生物工程療法，旨在透過激活人體自身的癒合反應來解決難癒合傷口的問題。這些療法旨在加速組織修復、縮短恢復時間並降低嚴重併發症（包括功能喪失）的風險。

預計到2025年，皮膚替代品市場規模將達到13億美元，並持續維持主導地位。這一主導地位歸功於其在為各種慢性及急性傷口提供結構支撐並促進組織再生方面的有效性。傷口發生率的長期持續上升將繼續推動對這些解決方案的持續需求。

到2025年，醫院領域將佔據43.7%的市場。醫療機構仍然是生物創傷護理產品的主要用戶，在治療各種傷口疾病方面發揮著至關重要的作用。採用包括生物來源敷料和再生醫學在內的先進治療方法，有助於改善傷口癒合效果，同時降低感染風險。

預計到2025年，美國生物製藥創傷護理產品市場規模將達到6.916億美元。慢性傷口負擔日益加重以及代謝性疾病病例的增加，持續推動市場需求。這些疾病嚴重影響患者的生活品質，因此迫切需要高效先進的傷口管理解決方案。

目錄

第1章：調查方法

• 研究途徑
• 品質改進計劃
  • GMI人工智慧政策和資料完整性計劃
    • 資訊來源一致性協議
• 調查過程和可靠性評分
  • 調查過程的組成部分
  • 評分組成部分
• 數據收集
  • 主要來源部分列表
• 資料探勘資訊來源
  • 付費資訊來源
    • 區域資訊來源
• 基本估算和計算方法
  • 每種方法中基準年的計算
• 預測模型
  • 量化市場影響分析
    • 生長參數對預測的數學影響
• 關於調查透明度的補充信息
  • 資訊來源歸屬框架
  • 品質保證指標
  • 對信任的承諾

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 開發中國家及低度開發地區燒燙傷增加
    • 全球老化進程
    • 創傷護理生物製劑的技術進步
    • 政府主導的傷口護理相關措施激增
  • 產業潛在風險與挑戰
    • 開發中國家缺乏訓練有素的醫生
    • 生物創傷護理產品高成本
  • 市場機遇
    • 在以價值為導向的醫療保健框架下，對具有成本效益的生物製藥的需求日益成長。
    • 人們對預防糖尿病足潰瘍（DFU）的興趣日益濃厚。
• 成長潛力分析
• 監理情勢
• 技術趨勢（基於初步調查）
  • 目前技術
    • 胎盤來源同種異體移植技術
    • 以膠原蛋白和細胞外基質為基底的傷口支架
  • 新興技術
    • 生物工程和下一代皮膚替代平台
    • 魚皮和新型異種移植生物平台
• 未來市場趨勢（基於初步研究）
• 價格分析（基於初步調查）
• 人工智慧和生成式人工智慧對市場的影響（基於初步研究）
• 波特五力分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 北美洲
  • 歐洲
  • 亞太地區
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 業務拓展計劃

第5章 市場估算與預測：依產品類型分類，2022-2035年

• 皮膚替代材料
  • 生物來源
    • 同種異體移植
    • 異質骨移植
    • 其他生物基皮膚替代品
  • 合成
• 外用製劑

第6章 市場估算與預測：依傷口類型分類，2022-2035年

• 糖尿病足潰瘍
• 下肢靜脈潰瘍
• 壓瘡
• 手術傷口
• 燒傷
• 其他傷口類型

第7章 市場估計與預測：依最終用途分類，2022-2035年

• 醫院
• 門診手術中心
• 其他用途

第8章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• 3M
• Amnio Technology
• Avita Medical
• Celularity Inc.
• Convatec
• Derma Sciences
• Integra Life Sciences
• Kerecis
• MiMedx Group
• Organogenesis
• Osiris Therapeutics
• Smith &Nephew
• Tides Medical
• Vericel Corporation

The Global Wound Care Biologics Market was valued at USD 2 billion in 2025 and is estimated to grow at a CAGR of 5.9% to reach USD 3.5 billion by 2035.

The industry is witnessing growth as healthcare systems increasingly prioritize advanced therapies for complex and chronic wounds. Rising cases of burn injuries, particularly in regions with limited access to advanced medical care, are contributing to higher demand for biologic wound solutions. Delayed treatment, inadequate infrastructure, and elevated infection risks often complicate healing processes, thereby strengthening the need for innovative biologic interventions. These solutions are gaining traction due to their ability to support tissue repair and improve recovery outcomes. In addition, the growing aging population is significantly influencing market dynamics, as older individuals are more susceptible to chronic wounds such as pressure injuries and diabetic-related complications. Increasing clinical focus on regenerative therapies, coupled with advancements in bioengineered products, is further supporting adoption. As healthcare providers emphasize faster healing and reduced complications, biologic wound care products are becoming integral to modern treatment protocols, reinforcing long-term market expansion.

Wound care biologics represent advanced bioengineered therapies developed to address difficult-to-heal wounds by activating natural healing responses within the body. These solutions are designed to enhance tissue repair, reduce recovery time, and lower the risk of severe complications, including loss of function.

The skin substitutes segment generated USD 1.3 billion in 2025, maintaining a leading position in the market. This dominance is attributed to their effectiveness in providing structural support while promoting tissue regeneration across both chronic and acute wound types. Increasing prevalence of long-term wounds continues to drive sustained demand for these solutions.

The hospitals segment accounted for 43.7% share in 2025. Healthcare facilities remain the primary users of biologic wound care products due to their critical role in treating a wide range of wound conditions. The adoption of advanced therapies, including biologically derived dressings and regenerative treatments, is helping improve healing outcomes while reducing infection risks.

U.S. Wound Care Biologics Market was valued at USD 691.6 million in 2025. The country's growing burden of chronic wounds, combined with increasing cases of metabolic conditions, continues to drive demand. These conditions significantly impact patient quality of life, creating a strong need for effective and advanced wound management solutions.

Key companies operating in the Wound Care Biologics Market include Amnio Technology, Convatec, Vericel Corporation, Organogenesis, Celularity Inc., Kerecis, Avita Medical, MiMedx Group, Derma Sciences, Integra Life Sciences, Smith & Nephew, Osiris Therapeutics, Tides Medical, and 3M. Companies in the Wound Care Biologics Market are focusing on strengthening their position through continuous innovation, strategic collaborations, and expansion into emerging markets. Many players are investing in research and development to introduce next-generation bioengineered products that enhance healing efficiency and reduce treatment time. Partnerships with healthcare providers and research institutions are helping accelerate product development and clinical validation. Firms are also expanding manufacturing capabilities to meet rising global demand while improving supply chain efficiency. In addition, companies are adopting advanced technologies to improve product performance and patient outcomes.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Product type trends
  • 2.2.2 Wound type trends
  • 2.2.3 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising burn injuries in developing and underdeveloped regions
    • 3.2.1.2 Increasing geriatric population globally
    • 3.2.1.3 Technological advancements in wound care biologics
    • 3.2.1.4 Surge in government initiatives regarding wound care treatment
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of trained physicians in underdeveloped economies
    • 3.2.2.2 High cost of biologic wound-care products
  • 3.2.3 Market opportunity
    • 3.2.3.1 Rising demand for cost-effective biologics under value-based care frameworks
    • 3.2.3.2 Growing focus on diabetic foot ulcer (DFU) prevention
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technological landscape (Driven by Primary Research)
  • 3.5.1 Current technologies
    • 3.5.1.1 Placental-derived allograft technologies
    • 3.5.1.2 Collagen and extracellular-matrix-based wound scaffolds
  • 3.5.2 Emerging technologies
    • 3.5.2.1 Bioengineered and next-generation skin substitute platforms
    • 3.5.2.2 Fish-skin and novel xenograft biologic platforms
• 3.6 Future market trends (Driven by Primary Research)
• 3.7 Pricing analysis (Driven by Primary Research)
• 3.8 Impact of AI and Generative AI on the market (Driven by Primary Research)
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2022-2035 ($ Mn)

• 5.1 Key trends
• 5.2 Skin substitutes
  • 5.2.1 Biological
    • 5.2.1.1 Allograft
    • 5.2.1.2 Xenograft
    • 5.2.1.3 Other biological skin substitutes
  • 5.2.2 Synthetic
• 5.3 Topical agents

Chapter 6 Market Estimates and Forecast, By Wound Type, 2022-2035 ($ Mn)

• 6.1 Key trends
• 6.2 Diabetic foot ulcers
• 6.3 Venous leg ulcers
• 6.4 Pressure ulcers
• 6.5 Surgical wounds
• 6.6 Burns
• 6.7 Other wound types

Chapter 7 Market Estimates and Forecast, By End Use, 2022-2035 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2022-2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 3M
• 9.2 Amnio Technology
• 9.3 Avita Medical
• 9.4 Celularity Inc.
• 9.5 Convatec
• 9.6 Derma Sciences
• 9.7 Integra Life Sciences
• 9.8 Kerecis
• 9.9 MiMedx Group
• 9.10 Organogenesis
• 9.11 Osiris Therapeutics
• 9.12 Smith & Nephew
• 9.13 Tides Medical
• 9.14 Vericel Corporation